PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
A61K 31/505, 31/52

A1

(11) International Publication Number: WO 00/66128

(43) International Publication Date: 9 November 2000 (09.11.00)

(21) International Application Number: PCT/US00/11353

(22) International Filing Date: 28 April 2000 (28.04.00)

(30) Priority Data:
60/132,003 30 April 1999 (30.04.99) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US 60/132,003 (CIP)
Filed on 30 April 1999 (30.04.99)

(71) Applicant *(for all designated States except US)*: CELL THERAPEUTICS, INC. [US/US]; 201 Elliot Avenue West, Suite #400, Seattle, WA 98119 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: NADLER, Jerry, L. [US/US]; 3121 Edgewater Drive, Charlottesville, VA 22911 (US). BALON, Thomas, W. [US/US]; 21042 East Arrow Highway, #83, Covina, CA 91724 (US). YAMAGUCHI, Yoko, Fujita [JP/US]; 1273 Indian Springs Drive, Glendora, CA 91741 (US).

(74) Agent: BENT, Stephen, A.; Foley & Lardner, 3000 K Street N.W., Suite 500, Washington, DC 20007–5109 (US).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: METHOD OF ENHANCING INSULIN ACTION

(57) Abstract

A category of hydroxyalkyl–substituted xanthines are useful in treating patients suffering from disorders associated with impaired glucose metabolism or impaired insulin function. Use of these compounds, for example, restores insulin responsiveness in otherwise insulin–resistant Type 2 diabetic patients, thus reducing elevated blood glucose levels. The subject compounds also act to restore certain defects of lipid metabolism and to enhance the effects of insulin in general. Insulin–enhancing compositions and methods of treating disorders of glucose metabolism are provided.